{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:23:11Z","timestamp":1793496191657,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13104-015-1548-3","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T05:24:35Z","timestamp":1445577875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia"],"prefix":"10.1186","volume":"8","author":[{"given":"Thomas A.","family":"O\u2019Bryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason F.","family":"Okulicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Agan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"issue":"6","key":"1548_CR1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-96-6-714","volume":"96","author":"L Morris","year":"1982","unstructured":"Morris L, Distenfeld A, Amorosi E, Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med. 1982;96(6):714\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1548_CR2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation.V2012.1.306.3798320","volume":"2012","author":"J Johnsen","year":"2012","unstructured":"Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program. 2012;2012(1):306\u201312.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"25","key":"1548_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJM199212173272503","volume":"327","author":"PJ Ballem","year":"1992","unstructured":"Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers H, Doubroff P, Mikulash K. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327(25):1779\u201384.","journal-title":"N Engl J Med"},{"issue":"3","key":"1548_CR4","first-page":"415","volume":"123","author":"Y Najean","year":"1994","unstructured":"Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med. 1994;123(3):415\u201320.","journal-title":"J Lab Clin Med"},{"issue":"3","key":"1548_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00042560-200111010-00003","volume":"28","author":"J Servais","year":"2001","unstructured":"Servais J, Nkoghe D, Schmit J-C, Arendt V, Robert I, Staub T, Moutschen M, Schneider F, Hemmer R. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(3):221\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"1548_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/jinf.2001.0833","volume":"42","author":"S Carbonara","year":"2001","unstructured":"Carbonara S, Fiorentino G, Serio G, Maggi P, Ingravallo G, Monno L, Bruno F, Coppola S, Pastore G, Angarano G. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect. 2001;42(4):251\u20136.","journal-title":"J Infect"},{"issue":"2","key":"1548_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00000441-200008000-00010","volume":"320","author":"DM Aboulafia","year":"2000","unstructured":"Aboulafia DM, Bundow D, Waide S, Bennet C, Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci. 2000;320(2):117\u201323.","journal-title":"Am J Med Sci"},{"issue":"6","key":"1548_CR8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.hoc.2009.08.009","volume":"23","author":"R Stasi","year":"2009","unstructured":"Stasi R, Willis F, Shannon MS, Gordon-Smith EC. Infectious causes of chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1275\u201397.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"1548_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/QAI.0b013e31817bec05","volume":"49","author":"AC Weintrob","year":"2008","unstructured":"Weintrob AC, Fieberg AM, Agan BK, Ganesan A, Crum-Cianflone NF, Marconi VC, Roediger M, Fraser SL, Wegner SA, Wortmann GW. Increasing age at HIV seroconversion from 18 to 40\u00a0years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr. 2008;49(1):40\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"1548_CR10","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/00002030-200311210-00016","volume":"17","author":"SK Brodine","year":"2003","unstructured":"Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR, McCutchan FE. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003;17(17):2521\u20137.","journal-title":"AIDS."},{"issue":"11","key":"1548_CR11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, K\u00fchne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"5","key":"1548_CR12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/QAI.0b013e3181be73e3","volume":"52","author":"M-A Bouldouyre","year":"2009","unstructured":"Bouldouyre M-A, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker J-P, Molina J-M, ANRS 106 Study Group. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-Window trial. J Acquir Immune Defic Syndr. 2009;52(5):531\u20137.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"8","key":"1548_CR13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/09537104.2011.582526","volume":"22","author":"V Vannappagari","year":"2011","unstructured":"Vannappagari V, Nkhoma ET, Atashili J, St. Laurent S, Zhao H. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy. Platelets. 2011;22(8):611\u20138.","journal-title":"Platelets"},{"issue":"5","key":"1548_CR14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0000000000000347","volume":"67","author":"M Franzetti","year":"2014","unstructured":"Franzetti M, Adorni F, Oreni L, Van Den Bogaart L, Resnati C, Milazzo L, Antinori S, Galli M, Ridolfo AL. Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiteroviral therapy. J Acquir Immune Defic Syndr. 2014;67(5):493\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1548_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QAI.0b013e3181b79aff","volume":"52","author":"KM Marks","year":"2009","unstructured":"Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;52(5):595\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1548_CR16","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2014. http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf . Accessed July 14 2014."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-015-1548-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T03:31:12Z","timestamp":1599708672000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1756-0500\/8\/595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1186\/s13104-015-1548-3","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,23]]},"article-number":"595"}}